Monitoring whilst taking antithyroid drugs
The CSM and MCA have made the following recommendations:
- patients taking antithyroid drugs should be asked to report symptoms suggestive of infection particularly sore throat
- if there is clinical evidence of infection then a FBC should be performed
- if there is clinical or laboratory evidence of neutropenia then the antithyroid drug should be stopped
- routine FBC monitoring is not indicated (1)
Reference:
- Current Problems in Pharmacovigilance (February 1999), 25, 1-4.
Related pages
Create an account to add page annotations
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.